TNSN08056A1 - Combinations comprising dmxaa for the treatment of cancer - Google Patents

Combinations comprising dmxaa for the treatment of cancer

Info

Publication number
TNSN08056A1
TNSN08056A1 TNP2008000056A TNSN08056A TNSN08056A1 TN SN08056 A1 TNSN08056 A1 TN SN08056A1 TN P2008000056 A TNP2008000056 A TN P2008000056A TN SN08056 A TNSN08056 A TN SN08056A TN SN08056 A1 TNSN08056 A1 TN SN08056A1
Authority
TN
Tunisia
Prior art keywords
combinations
dmxaa
cancer
treatment
compounds
Prior art date
Application number
TNP2008000056A
Other languages
English (en)
Inventor
Colin Green
Lloyd Kelland
Gail Rowlinson-Busza
Original Assignee
Antisoma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517386A external-priority patent/GB0517386D0/en
Priority claimed from GB0604114A external-priority patent/GB0604114D0/en
Application filed by Antisoma Res Ltd filed Critical Antisoma Res Ltd
Publication of TNSN08056A1 publication Critical patent/TNSN08056A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
TNP2008000056A 2005-08-26 2008-02-06 Combinations comprising dmxaa for the treatment of cancer TNSN08056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0517386A GB0517386D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer
GB0604114A GB0604114D0 (en) 2006-03-02 2006-03-02 Combinations for the treatment of cancer
PCT/GB2006/003196 WO2007023302A1 (en) 2005-08-26 2006-08-25 Combinations comprising dmxaa for the treatment of cancer

Publications (1)

Publication Number Publication Date
TNSN08056A1 true TNSN08056A1 (en) 2009-07-14

Family

ID=37429252

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000056A TNSN08056A1 (en) 2005-08-26 2008-02-06 Combinations comprising dmxaa for the treatment of cancer

Country Status (14)

Country Link
US (1) US20100297112A1 (ru)
EP (1) EP1917011A1 (ru)
JP (1) JP2009506019A (ru)
KR (1) KR20080047402A (ru)
AU (1) AU2006283371A1 (ru)
BR (1) BRPI0614965A2 (ru)
CA (1) CA2620436A1 (ru)
EC (1) ECSP088243A (ru)
IL (1) IL189376A0 (ru)
MA (1) MA29786B1 (ru)
NO (1) NO20080649L (ru)
RU (1) RU2404764C2 (ru)
TN (1) TNSN08056A1 (ru)
WO (1) WO2007023302A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CA2708149A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
EP0961617A4 (en) * 1996-12-13 2002-08-07 Lilly Co Eli LEUKOTRINE ANTAGONISTS FOR TREATING FOCAL BRAIN CHEMISTRY
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
ES2234523T3 (es) * 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
AU5717400A (en) * 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
AU2001282717A1 (en) * 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP1620547B1 (en) * 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
RU2404764C2 (ru) 2010-11-27
WO2007023302A1 (en) 2007-03-01
CA2620436A1 (en) 2007-03-01
MA29786B1 (fr) 2008-09-01
RU2008111492A (ru) 2009-10-10
JP2009506019A (ja) 2009-02-12
AU2006283371A1 (en) 2007-03-01
BRPI0614965A2 (pt) 2016-09-13
US20100297112A1 (en) 2010-11-25
IL189376A0 (en) 2008-06-05
EP1917011A1 (en) 2008-05-07
NO20080649L (no) 2008-05-26
ECSP088243A (es) 2008-08-29
KR20080047402A (ko) 2008-05-28

Similar Documents

Publication Publication Date Title
TNSN08056A1 (en) Combinations comprising dmxaa for the treatment of cancer
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
AU2003282215A1 (en) Anti-cancer composition comprising dmxaa or related compound
TN2009000194A1 (en) Novel antiproliferation antibodies
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
Mah et al. The effect of epigallocatechin-3-gallate (EGCG) on human alveolar bone cells both in vitro and in vivo
HK1071066A1 (en) Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
UA102867C2 (ru) Антитела к cxcr4 и их применение в лечении рака
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
EA200800427A1 (ru) Композиция для сдерживания алкогольного обмена веществ и для уменьшения риска алкогольных заболеваний
UA92025C2 (en) Indole compounds
WO2008027739A3 (en) Antibodies to ntb-a
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
TNSN08057A1 (en) Combinations comprising dmxaa for the treatment of cancer
WO2009051957A3 (en) Antibodies to irem-1
Kutleša et al. Wine and bone health: a review